1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Charmacy Pharmaceutical Co., Ltd. Class H

Charmacy Pharmaceutical Co., Ltd. Class H

HHKEX:2289
5.50
HKD
+0.00
(-0.09%)
1.06BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
37.68
41.63
33.98
37.92
36.44
32.34
36.96
35.13
38.66
40.77
41.07
40.6
- -
Basic EPS, GAAP
0.46
0.32
0.52
0.41
0.42
0.37
0.38
0.21
0.84
0.48
0.49
0.43
- -
Free Cash Flow per Basic Share
-0.24
2
-1.14
-1.47
-0.45
-0.65
0.73
-0.41
0.33
-1.27
0.84
- -
- -
Dividend per Share
- -
0.56
0.34
0.47
0.45
0.57
0.52
0.49
0.26
0.7
0.59
0.75
- -
Book Value per Share
2.27
3.84
4.1
4.22
4.41
4.48
4.65
4.67
5.51
5.54
5.73
5.71
5.73
Tangible Book Value per Share
2.27
3.84
3.09
2.69
2.91
3.03
3.19
3.29
4.71
4.77
5
5.02
5
Basic Weighted Avg Shares
80
82
108
108
108
108
108
108
108
108
108
108
108
Sales/Revenue/Turnover
3,014
3,397
3,670
4,096
3,935
3,493
3,992
3,794
4,175
4,404
4,435
4,385
- -
Operating Margin (%)
2.12
1.8
2.46
2.24
2.58
2.67
2.64
2.06
2.4
2.61
3.15
3.4
- -
Depreciation Expense
12
11
11
14
19
25
14
33
33
29
35
35
- -
Net Income, GAAP
36
26
56
45
45
40
41
23
90
51
53
46
- -
Effective Tax Rate (%)
20.66
36.6
25.79
26
29.68
27.05
25.91
29.8
25.88
23.84
25.15
28.05
- -
Profit Margin (%)
1.21
0.78
1.54
1.09
1.15
1.15
1.02
0.61
2.17
1.17
1.2
1.06
- -
Working Capital
49
199
213
96
176
140
89
79
207
193
241
280
241
LT Debt
- -
- -
- -
- -
90
141
134
99
16
30
49
62
49
Total Equity
246
414
443
463
477
484
503
504
595
598
619
616
619
Return on Invested Capital (%)
- -
6.64
7.12
2.98
2.28
2.1
1.83
1.06
4.28
2.36
2.41
1.92
- -
Return on Capital (%)
- -
6.65
9.3
4.75
3.73
3.35
3.1
2.45
5.65
3.96
4.41
3.47
- -
Return on Common Equity (%)
- -
7.99
13.18
9.96
9.74
8.36
8.23
4.6
16.46
8.61
8.76
7.49
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
1,531
1,619
1,648
LT Borrowings
- -
- -
14
LT Finance Leases
30
40
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
108
108
108
Market Capitalization
1,272
864
995

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
2,812
2,833
3,030
Cash, Cash Equivalents & STI
634
404
563
Accounts Receivable, Net
962
1,039
1,163
Inventories
776
798
656
Total Current Liabilities
2,619
2,638
2,789
Payables & Accruals
- -
- -
- -
ST Debt
1,531
1,619
1,648
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.17%
4.38%
-0.38%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
27.96%
39.04%
-13.16%
Sales/Revenue/Turnover
2.89%
2.03%
-1.15%
Total Cash Common Dividend
15.51%
24.59%
25.39%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4,404
2024
- -
- -
4,435
2025
- -
- -
4,385

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.48
2024
- -
- -
0.49
2025
- -
- -
0.43

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.7
2024
- -
- -
0.59
2025
- -
- -
0.75

Company Description

Company Profile APIChatGPT
CEO
Chuanglong Yao
Full Time Employees
847
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 235, Song Shan North Road Shantou GD China 515041
IPO Date
Dec 14, 2015
Website
chmyy.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Charmacy Pharmaceutical Co., Ltd. (2289.HK) engages in the distribution of pharmaceutical products primarily in the People's Republic of China, with operations centered in the Pearl River Delta region including Guangdong, Zhuhai, and Guangzhou. The company distributes western medicines, Chinese patent medicines, healthcare products, traditional Chinese medicine materials and decoction pieces, medical devices, and cosmetic products to downstream distributors, retail pharmacies, hospitals, clinics, and health centers; it also provides pharmaceutical product-related consulting services and third-party logistics for medicines, supported by large logistics centers in Shantou and Foshan, professional transport teams, and modern information systems. Additionally, Charmacy operates the Charmacy e-Medicine B2B e-commerce platform, enabling online order placement, inquiries, payments, fast search, code scanning, and settlement to enhance sales efficiency and customer experience for its over 11,000 pharmaceutical products. Founded in 1984 as Chuangmei Pharmaceutical Co., Ltd. and renamed Charmacy Pharmaceutical Co., Ltd. in July 2016, the company is headquartered at No. 235, Song Shan North Road, Longhu District, Shantou City, Guangdong Province, China, with its H shares listed on the Hong Kong Stock Exchange since December 2015. Recent developments include the approval of strategic agreements with Jiangyao Group in December 2024 for the sale and purchase of pharmaceutical products, strengthening distribution arrangements and market position following unanimous shareholder support at the 2024 Second Extraordinary General Meeting; partnerships with leading brands such as Dong-E E-Jiao, Fosun Pharma, and Hainan in the latest reporting period; and acquisitions of Zhuhai Chuangmei Hengxiang Pharmaceutical Co., Ltd. and Guangzhou Charmacy Pharmaceutical Co., Ltd. in the first half of 2017 to expand its network.